Loading…
Reported covered position: Legislative Assistant/Legislative Director Congressman Stephen F. Lynch
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2026 · third_quarter · Q3
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Source: Senate LDA
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Mikaela Naylon Give Kids a Chance Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act of 2025
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
PSA Screening for HIM Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Accelerating Kids’ Access to Care Act
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Gabriella Miller Kids First Research Act 2.0
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
PATIENT Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
PATIENT Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
PATIENT Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
PATIENT Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
PATIENT Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
PATIENT Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
PATIENT Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
PREVENT HPV Cancers Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
To amend title XVIII of the Social Security Act to provide coverage for wigs as durable medical equipment under the Medicare program, and for other purposes.
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
CONNECT for Health Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
CONNECT for Health Act of 2023
Client: DANA-FARBER CANCER INSTITUTE · Firm: DANA-FARBER CANCER INSTITUTE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2026 · second_quarter · Q2
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2026 · first_quarter · Q1
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2025 · fourth_quarter · 4A
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2025 · fourth_quarter · Q4
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2025 · third_quarter · Q3
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2025 · second_quarter · Q2
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2025 · first_quarter · Q1
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Issues related to quality of life, survivorship and access for cancer patients including HR 1509/ S 752 the Accelerating Kids Access to Care Act, HR 1262 the Give Kids a Chance Act and HR 1300/S 297 the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2024 · fourth_quarter · Q4
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2024 · first_quarter · 1A
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2024 · second_quarter · 2A
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2024 · third_quarter · 3A
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2024 · third_quarter · Q3
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2024 · second_quarter · Q2
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2024 · first_quarter · Q1
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · fourth_quarter · Q4
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · third_quarter · Q3
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869). Issues related to the oncology drug shortage and various efforts to address.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · second_quarter · Q2
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program.
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544).
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · first_quarter · 1A
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act, a bill to provide coverage for wigs as durable medical equipment under the Medicare program, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including the Connect for Health Act among other telehealth bills.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2023 · first_quarter · Q1
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act, a bill to provide coverage for wigs as durable medical equipment under the Medicare program, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including the Connect for Health Act among other telehealth bills.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · fourth_quarter · Q4
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · third_quarter · 3A
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · third_quarter · Q3
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for ARPA-H in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill; FY 2023 Funding for a potential Therapeutic Food Pantry project at DFCI.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · second_quarter · Q2
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2022 · first_quarter · Q1
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to quality of life, survivorship and access for cancer patients including Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills.
Funding related to biomedical and cancer research and innovation at the NIH and NCI including the omnibus appropriation for Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022; funding for the NIH,NCI and ARPA-H;HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine; FY 2023 Funding for the NIH and NCI and a potential Therapeutic Food Pantry project at DFCI.
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2021 · fourth_quarter · Q4
Issues related to quality of life, survivorship and access for cancer patients including Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021; S. 610, Protecting Medicare and American Farmers from Sequester Cuts Act
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2021 · third_quarter · Q3
Issues related to quality of life, survivorship and access for cancer patients including Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; CURES 2.0 Discussion Draft
DANA-FARBER CANCER INSTITUTE via DANA-FARBER CANCER INSTITUTE
2021 · third_quarter · RR
ARPA-H initiative, funding for National Institutes of Health, National Cancer Institute, Telehealth issues, etc.
ARPA-H initiative, funding for National Institutes of Health, National Cancer Institute, Telehealth issues, etc.
ARPA-H initiative, funding for National Institutes of Health, National Cancer Institute, Telehealth issues, etc.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare and Medicare Advantage program
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including 1509/ S 752 the Accelerating Kids Access to Care Act and HR 1262 the Give Kids a Chance Act
Support for FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars. Support for continued funding for the CDCs Office on Smoking and Health.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, President of the U.S., SENATE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; funding for cancer prevention and smoking cessation programs at the CDC.
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869) and other matters related to provider reimbursement. Issues related to the oncology drug shortage and various efforts to address.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE
Issues related to quality of life, survivorship and access for cancer patients including the Comprehensive Cancer Survivorship Act (HR 4363) a bill to provide coverage for wigs as durable medical equipment under the Medicare program (HR 4034), the Palliative Care and Hospice Education and Training Act, (S 2443) Extension of federal telehealth policies post-pandemic including the Connect for Health Act (HR 4189, S 2016) among other telehealth bills, the PREVENT HPV Cancers Act(HR 3633) the Accelerating Kids' Access to Care Act (HR 3089, S 1544)and The Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869). Issues related to the oncology drug shortage and various efforts to address.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors, menthol and small cigars.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544); Innovation in Pediatric Drugs Act of 2023 (HR 6664)
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), President of the U.S., SENATE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bill; FY 2024 Funding for a potential Therapeutic Food Pantry project and freezers for research labs at DFCI.
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including Gabriella Miller Kids First Research Act 2.0 (HR 3391, S 1624); Accelerating Kids Access to Care Act(HR 3089, S 1544)
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act (HR 15, S 5).
Support for LIFT the BAR Act (HR 4170, S 2038) which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality; prior authorization in the Medicare program.
Support for the LIFT the BAR Act which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to the civil rights of our employees, patients, and their families such as the Equality Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Support for the LIFT the BAR Act which would restore access to programs like Medicaid, CHIP, and SNAP by removing the five-year bar and other barriers that deny critical care and aid to people who are lawfully present.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality; prior authorization in the Medicare program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors and small cigars.
Tax issues that impact patients and their families including HR3321 / S1670 - Credit for Caring Act of 2021
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for ARPA-H in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill;
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act and reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Tax issues that impact patients and their families including HR3321 / S1670 - Credit for Caring Act of 2021
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for ARPA-H in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill; FY 2023 Funding for a potential Therapeutic Food Pantry project at DFCI.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors and small cigars.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 5376, the Inflation Reduction Act, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Issues related to access to critical health and social services for lawfully present immigrant families such as HR 5227, the Lift the Bar Act and Public Charge regulations.
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors and small cigars.
Tax issues that impact patients and their families including HR3321 / S1670 - Credit for Caring Act of 2021
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Issues related to quality of life, survivorship and access to care and therapeutics for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act; HR 5376, the Inflation Reduction Act and HR 3630/S 1315 Lymphedema Treatment Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), SENATE
Supporting FDA's role to vigorously enforce the Family Smoking Prevention and Tobacco Control Act including the regulation of flavors and small cigars.
Funding related to biomedical and cancer research and innovation at the NIH and NCI in the Labor, Health and Human Services, Education bill; Tobacco control policies in the Agriculture, Rural Development, FDA & Related Agencies appropriations bill funding for ARPA-H; HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine; FY 2023 Funding for a potential Therapeutic Food Pantry project at DFCI.
Issues related to quality of life, survivorship and access for cancer patients including S. 4260, the Palliative Care and Hospice Education and Training Act; Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills; reform of the oversight of Laboratory Developed Tests as outlined in S.2209/HR 4128 the VALID Act and S 3799 the PREVENT Pandemics Act.
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021 and Extension of federal telehealth policies post-pandemic including S. 1512, the Connect for Health Act among others telehealth bills
Tax issues that impact patients and their families including HR3321 / S1670 - Credit for Caring Act of 2021
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Tax issues that impact patients and their families including HR3321 / S1670 - Credit for Caring Act of 2021
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Support policies to remove barriers to clinical trials, promote research generally, address issues in childhood cancer research including HR5030 / S2706 - The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act; HR623 / S1521 - Gabriella Miller Kids First Research Act 2.0; HR3089 / S1544 Accelerating Kids Access to Care Act; HR 6000, CURES 2.0 Act; H.R. 5585, the Advanced Research Project Agency-Health (ARPA-H) Act
Funding related to biomedical and cancer research and innovation at the NIH and NCI including HR 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022; funding for the NIH,NCI and ARPA-H;HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine; H.R.6119 - Further Extending Government Funding Act
Tax issues that impact patients and their families including HR3321 / S1670 - Credit for Caring Act of 2021
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act;
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
Issues related to the civil rights of our employees, patients, and their families such as HR5 / S393 - the Equality Act
Funding related to biomedical and cancer research and innovation at the NIH and NCI including HR 4502, Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022; funding for the NIH,NCI and ARPA-H;HR 5376, Build Back Better Act-include policies related to the establishment of ARPA-H, lymphedema treatment access, palliative care and telemedicine
Tax issues that impact patients and their families including HR3321 / S1670 - Credit for Caring Act of 2021
Issues related to health care access and reimbursement through the Medicare and Medicaid programs including, HR 1948/ S 518 The Lymphedema Treatment Act, HR 3149/S 1660 HEAL for Immigrant Families Act of 2021
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE